Wendy Wee - Net Worth and Insider Trading

Wendy Wee Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Wendy Wee owns 2 companies in total, including Kindred Biosciences Inc (KIN) , and MabVax Therapeutics Holdings Inc (MBVXQ) .

Click here to see the complete history of Wendy Wee’s form 4 insider trades.

Insider Ownership Summary of Wendy Wee

Ticker Comapny Transaction Date Type of Owner
KIN Kindred Biosciences Inc 2020-01-22 Chief Financial Officer
MBVXQ MabVax Therapeutics Holdings Inc 2011-05-25 VP & Finance & Controller

Wendy Wee Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Wendy Wee Ownership Network

Ownership Network List of Wendy Wee

No Data

Ownership Network Relation of Wendy Wee

Insider Network Chart

Wendy Wee Owned Company Details

What does Kindred Biosciences Inc do?

Who are the key executives at Kindred Biosciences Inc?

Wendy Wee is the Chief Financial Officer of Kindred Biosciences Inc. Other key executives at Kindred Biosciences Inc include director & Chief Executive Officer Richard Chin , 10 percent owner Park West Asset Management Llc , and Chief Scientific Officer Hangjun Zhan .

Kindred Biosciences Inc (KIN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kindred Biosciences Inc (KIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kindred Biosciences Inc (KIN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kindred Biosciences Inc (KIN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Kindred Biosciences Inc Insider Transactions

No Available Data

Wendy Wee Mailing Address

Above is the net worth, insider trading, and ownership report for Wendy Wee. You might contact Wendy Wee via mailing address: C/o Telik, Inc. 700 Hansen Way Palo Alto Ca 94304.

Discussions on Wendy Wee

No discussions yet.